Related Experiment Video
Updated: Jun 8, 2025

07:57
An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
Published on: April 11, 2018
6.9K
Cerebral hyperactivation across the Alzheimer's disease pathological cascade
Nick Corriveau-Lecavalier1,2, Jenna N Adams3, Larissa Fischer4
1Department of Neurology, Mayo Clinic, Rochester, Minnesota 55902, USA.
Brain Communications
|November 8, 2024
Summary
Alzheimer's disease shows brain hyperactivation, possibly compensatory or pathological. Understanding this fMRI signal is key for disease models and interventions.
Area of Science:
- Neuroscience
- Medical Imaging
- Gerontology
Background:
- Neuronal dysfunction is central to Alzheimer's disease (AD).
- Early AD often shows increased functional MRI (fMRI) blood oxygenation level-dependent signal (hyperactivation) during tasks.
- Existing research presents complex and conflicting findings on hyperactivation patterns and their interpretation.
Purpose of the Study:
- To provide a coherent narrative for discrepancies in fMRI hyperactivation findings in Alzheimer's disease.
- To explore the relationship between hyperactivation and Alzheimer's pathology.
- To propose a framework for understanding hyperactivation in the context of aging, cognition, and AD progression.
Main Methods:
- Comprehensive review of functional brain changes from normal aging to AD spectrum.
- Focus on task-based fMRI studies in humans.
- Consideration of other functional imaging techniques and animal models.
Main Results:
- Hyperactivation patterns vary with disease stage, brain regions, and fMRI paradigms.
- Evidence suggests a link between fMRI hyperactivation and in vivo markers of AD pathology.
- Hyperactivation may reflect compensatory mechanisms or pathological disruption.
Conclusions:
- Clarifying the nature of hyperactivation is crucial for developing AD disease models.
- Understanding hyperactivation's role in the AD cascade can inform targeted interventions.
- Future research should focus on a testable framework linking hyperactivation, aging, cognition, and AD pathology.
Related Concept Videos
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482

